- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03497624
ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
ROS1-fusions occur in several cancer types such as non-small cell lung cancer, gastric cancer, ovarian cancer, glioblastoma, cholangiocarcinoma and melanoma. In each of these cancers, ROS1-fusions account for a small sliver of the pie, accounting for 1-2% of all diagnoses, forming a relatively rare molecular subset of cancer. The Addario Lung Cancer Medical Institute (ALCMI) would like to focus on this under-studied rare molecular subset of cancer to understand how cancer begins and spreads in these tumors, how these tumors respond to treatment and what happens when tumors stop responding to treatment. Therefore, in collaboration with cancer patients whose tumors have ROS1-fusions (known as the "ROS1ders"), we are studying ROS1-fusions across all cancer types.
Patient Derived Xenografts (PDXs) are models to study cancer. These models are developed by injecting a fresh piece of tumor specimen from a patient into a special type of mouse, which then acts as 'host' to allow the tumor to grow. Peer-reviewed and published experimental studies have shown that PDX models can maintain features similar to the original tumor from the patient. PDX models can be used to study tumor growth, response to anti-cancer therapies, and resistance to anti-cancer therapies.
The purpose of this study is to develop up to 24 PDX models for ROS1-fusion driven cancers to be used for research purposes only. That is, these patient derived PDX models will have no immediate benefit to the patient from whom the tumor specimen was obtained. Rather, these PDX models will be used to inform the study of ROS1-fusion driven cancers at large.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
San Carlos, California, United States, 94040
- ALCMI
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female greater than 18 years of age at the time of consent.
- Confirmed diagnosis of ROS1-fusion positive tumor via IHC, FISH and/or NGS.
- A clinically-indicated procedure (required by the patient's treating physician) scheduled no more than 30 calendar days from date of consent.
- A minimum of 21 calendar days between the last dose of systemic therapy and the clinically-indicated procedure.
- A minimum of 42 hours between the last dose of a tyrosine kinase inhibitor (TKI) and the time of the clinically-indicated procedure.
- Willingness to undergo all study collection procedures and follow up.
- Provision of written informed consent by the patient.
- Able to communicate (read, write and speak) in English.
- Clinically-indicated procedure to be performed within the US (including Alaska, Hawaii and Puerto Rico), Canada, England, or Israel.
Exclusion Criteria:
- Less than 18 years of age at time of consent.
- No confirmed diagnosis of ROS1-fusion positive tumor via IHC, FISH and/or NGS.
- A biopsy or surgical procedure not scheduled for clinical/diagnostic purposes.
- A clinically-indicated procedure scheduled more than 30 calendar days from the date of consent.
- Receipt of systemic therapy less than 21 days from the time of the clinically-indicated procedure.
- Receipt of tyrosine kinase inhibitor less than 42 hours from the time of the clinically-indicated procedure.
- Unwilling to undergo all study collection procedures and follow up.
- Unable or unwilling to provide consent.
- Unable to communicate in English.
- Clinically-indicated procedure not scheduled within the US, Canada, England, or Israel.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary objective is to develop a unique cohort of PDX models for ROS1-fusion driven cancers as a resource to the research community.
Time Frame: 1 year
|
Successful generation of at least ten (10), but no more than twenty-four (24), ROS1-fusion PDX models with full characterization including whole exome sequencing (WES) and RNA sequencing.
Models can be used as a resource for clinical and translational research to understand mechanisms of resistance and develop new therapies.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The secondary/exploratory objectives are to enhance scientific knowledge of how to diagnose and treat ROS1-fusion driven cancers.
Time Frame: 24 months
|
These models will be made available to researchers to enhance scientific knowledge of how to diagnose and treat ROS1-fusion driven cancers.
|
24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Christine Lovly, MD, PhD, Vanderbilt University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- ALCMI-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ROS1-fusion Positive Tumor
-
Sameek RoychowdhuryNational Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ALK Gene Mutation | Metastatic Malignant Neoplasm in the Brain | Advanced Malignant Neoplasm | ALK Fusion Protein Expression | Metastatic Malignant Neoplasm in the Central Nervous System | ROS1 Gene Mutation | ALK Gene... and other conditionsUnited States
-
University of California, San FranciscoTerminatedALK Fusion Protein Expression | Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma | ROS1 Fusion Positive | BRAF wt Allele | Invasive Skin Melanoma | MET Fusion Gene Positive | NRAS wt Allele | NTRK1 Fusion... and other conditionsUnited States
-
Jiangsu Simcere Pharmaceutical Co., Ltd.RecruitingAdvanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene FusionChina
-
Centre Leon BerardRecruitingCancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditionsFrance, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedLocally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionChina
-
BayerRecruitingLocally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionUnited States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
-
Dr Joanne CHIURecruitingALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung CancerHong Kong
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
BayerCompletedAdvanced or Recurrent Solid Tumor Harboring an NTRK Gene FusionJapan
-
University of California, San FranciscoRecruitingSpinal Stenosis | Spine Fusion | Spine TumorUnited States
Clinical Trials on Biospecimens collection
-
Glicksman, Caroline, M.D.The Aesthetic Surgery Education & Research FoundationActive, not recruitingWomen With Breast Implants With and Without Self-reported Systemic Symptoms | Women Undergoing an Elective Mastopexy (Breast Lift) or Small ReductionUnited States
-
Hospices Civils de LyonCompletedDigestive Peritoneal CarcinomatosisFrance
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedNonsmall Cell Lung Cancer | Nonsmall Cell Lung Cancer StageUnited States
-
University Health Network, TorontoRecruiting
-
GlaxoSmithKlineCompleted
-
Medical University of South CarolinaActive, not recruitingHead and Neck CancerUnited States
-
University of FloridaNational Institute of General Medical Sciences (NIGMS)Recruiting
-
GlaxoSmithKlineCompletedInfections, CytomegalovirusFinland, United States, Mexico
-
LLS PedAL Initiative, LLCNational Cancer Institute (NCI); Children's Oncology GroupRecruitingAcute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Myeloid Leukemia Associated With Down Syndrome | Mixed Phenotype Acute Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy | Myelodysplastic Syndrome Post Cytotoxic TherapyUnited States, Canada, Australia, Puerto Rico, New Zealand
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)Active, not recruiting